Levadex

CAS : 511-12-6

Ref. TR-L511125

Informations sur le produit

• Nom: Levadex
• Synonymes: Dihydroergotamine, DHE, MAP 0004, 9,10-Dihydroergotamine, (5'alpha,10alpha)-9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trione, (5'Alpha,10Alpha)-5'-Benzyl-12'-Hydroxy-2'-Methyl-3',6',18-Trioxo-9,10-Dihydroergotaman, (5′α,10α)-9,10-Dihydro-12′-hydroxy-2′-methyl-5′-(phenylmethyl)ergotaman-3′,6′,18-trione, 8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine, ergotaman-3′,6′,18-trione deriv., Dihidroergotamina, Dihydroergotamin, Dihydroergotamine base, Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'α,10α)-, Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-methyl-5′-(phenylmethyl)-, (5′α,10α)-, Ergotamine, 9,10-dihydro-, Indolo[4,3-fg]quinoline, ergotaman-3′,6′,18-trione deriv., Map 0004

Description

Applications Levadex is an intermediate in the synthesis of 2’-Epidihydroergotamine (E584910), which is an ergot alkaloid that exhibits potential neuroprotective properties against degenerative diseases.
References French, W.N., et al.: J. Pharma. Sci., 54, 1515 (1965);

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 583.68
• Formule: C₃₃H₃₇N₅O₅
• InChI: InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23+,25-,26+,27+,32+,33+/m0/s1
• Code InChI: InChIKey=LUZRJRNZXALNLM-HDSVXBTFSA-N
• SMILES: CN1C[C@@H](C(=O)N[C@]2(C)O[C@]3(O)[C@H]4CCCN4C(=O)[C@@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@@H]21